HMW-adiponectin associates with triglyceride concentrations in type 1 diabetic patients

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 207-216

  Maruyama, Chizuko ^a   Ishibashi, Rieko ^a   Araki, Risa ^a   Koike, Shino ^a   Hirose, Hiroshi ^b   Maruyama, Taro ^c  

^a JAPAN WOMEN'S UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

Author keywords

ApoB48; Insulin therapy; Postprandial; RLP triglyceride

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B48; HIGH MOLECULAR WEIGHT ADIPONECTIN; INSULIN DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID METABOLISM; MALE; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350231555     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E067     Document Type: Article

References (40)

1. Ravussin E, Smith SR: Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci, 2002; 967:363-378
2. Katsuda Y, Asano A, Murase Y, Chujo D, Yagi K, Kobayashi J, Mabuchi H, Yamagishi M: Association of genetic variation of the adiponectin gene with body fat distribution and carotid atherosclerosis in Japanese obese subjects. J Atheroscler Thromb, 2007; 14:19-26
3. Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol, 2002; 47:173-180
4. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond), 2002; 103:137-142
5. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Kazuhisa M, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentration of a novel, adipose-spesific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000; 20:1595-1599
6. Havel PJ: Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 2004; 53 Suppl 1:S143-151
7. Hitsumoto T, Takahashi M, Iizuka T, Shirai K: Relationship between metabolic syndrome and early stage coronary atherosclerosis. J Atheroscler Thromb, 2007; 14:294-302
8. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 2002; 51:1884-1888
9. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogeneous glucose production in inhibited by the adipose-derived protein Acrp30. J Clin Invest, 2001; 108:1875-1881
10. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 2003; 52:239-243
11. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Yamagata K, Miyagawa J, Matsuzawa Y: Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care, 2002; 25:1665-1666
12. Barne MM, Curran-Everett D, Hamman RF, Maahs D, Mayer-Davis EJ, D'Agostino RB Jr, West N, Dabelea D: Determinants of adiponectin levels in young people with Type 1 diabetes. Diabetic Med, 2008; 25:365-369
13. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G: Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 2002; 25:971-976
14. Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ: The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia, 2005; 48:41-48
15. Grundy SM, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard WJ, Savage P, Sowers J, Vega GL: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. Circulation, 2002; 105:e153-e158
16. Ministry of Health Labour, and Welfare, Japan. Dietary reference intakes for Japanese, 2005. http://www.mhlw.go.jp/houdou/2004/11/h1122-2a.html
17. Karamanos BG, Thanopoulou AC, Roussi-Penesi DP: Maximal post-prandial triglyceride increase reflects post-prandial hypertriglyceridaemia and is associated with the insulin resistance syndrome. Diabete Med, 2001; 18:32-39
18. Martos-Moreno GA, Barrios V, Soriano-Guillén L, Argente J: Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur J Endocrinol, 2006; 155:757-761
19. Lindström T, Frystyk J, Hedman CA, Flyvbjerg A, Arnqvist HJ: Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration. Clin Endocrinol (Oxf), 2006; 65:776-782
20. Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, Roussel R, Marre M: SURGENE Study Group; DESIR Study Group. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia, 2005; 48:1088-1092
21. Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, Flyvbjerg A, Groop PH; FinnDiane study group: Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care, 2005; 28:1410-1414
22. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem, 2002; 277:19521-19529
23. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension, 2003; 42:76-81
24. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T: Peroxisome proliferator-activated receptor (PPAR) a activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. Diabetes, 2005; 54:3358-3370
25. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriuyma H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002; 51:2734-2741
26. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF: Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol, 2006; 26:1357-1363
27. Yamamoto T, Hirano T, Mori Y, Tokuno A, Nagashima M, Takeda M, Morita R, Lee S, Hayashi T, Adachi M: Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy. J Atheroscler Thromb, 2008; 15:199-205
28. Matikainen N, Manttari S, Wsterbacka J, Vehkavaara S, Lundbom N, Yki-Järvinen H, Taskinen MR: Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab, 2007; 92:3052-3059
29. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G: Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology, 2007; 45:1097-1107
30. Masuda D, Hirano KI, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y, Takeda M, Tsubakio-Yamamoto K, Tochino Y, Koseki M, Matsuura F, Nishida M, Kawamoto T, Ishigami M, Hori M, Shimomura I, Yamashita S: Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res, 2008; Epub ahead of print
31. Paglialunga S, Cianflone K: Regulation of postprandial lipemia: an update on current trends. Appl Physiol Nutr Metab, 2007; 32:61-75
32. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K: Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract, 2007; 76:93-101
33. De Vries R, Wolffenbuttel BH, Sluiter WJ, van Tol A, Dullaart RP: Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clin Lab, 2005; 51:403-409
34. Von Eynatten M, Schneider JG, Humpert PM, Rudofsky G, Schmidt N, Barosch P, Hamann A, Morcos M, Kreuzer J, Bierhaus A, Nawroth PP, Dugi KA: Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance Diabetes Care, 2004; 27:2925-2929
35. Kobayashi J, Kusunoki M, Murase Y, Kawashiri M, Higashikata T, Miwa K, Katsuda S, Takata M, Asano A, Nohara A, Inazu A, Mabuchi H: Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. Horm Metab Res, 2005; 37:505-509
36. Qiao L, Zou C, van der Westhuyzen DR, Shao J: Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes, 2008; 57:1824-1833
37. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T: Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem, 2004; 279:30817-30822
38. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T: Targeted disruption of Adipo R1 and Adipo R2 causes abrogation of adiponectin binding and metabolic actions. Nat Med, 2007; 13:332-339
39. Zeng Q, Fu L, Takekoshi K, Kawakami Y, Isobe K: Effects of short-term exercise on adiponectin and adiponectin receptor levels in rats. J Atheroscler Thromb, 2007; 14:261-265
40. O'Leary VB, Jorett AE, Marchetti CM, Gonzalez F, Phillips SA, Ciaraldi TP, Kirwan JP: Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab, 2007; 293:E421-427